3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Gynecologic
1
Dermatologic
1
Conditions
Melanoma
3
Warts
1
Uveal Melanoma
1
Tuberous Sclerosis
1
Seizures
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lennox Gastaut Syndrome
1
Hyperthermia
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioblastoma
1
Epilepsies, Myoclonic
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
12
Biopsy
10
Specimen Handling
9
Whole-Body Irradiation
7
Magnetic Resonance Spectroscopy
7
pembrolizumab
6
Peripheral Blood Stem Cell Transplantation
6
Melphalan
6
Etoposide
6
fludarabine
5
duvelisib
5
Brentuximab Vedotin
5
ruxolitinib
4
fludarabine phosphate
4
Vincristine
4
Prednisone
4
Doxorubicin
4
Cytarabine
4
10-propargyl-10-deazaaminopterin
4
romidepsin
3
X-Rays
3
Mycophenolic Acid
3
Immunoglobulin G
3
Granulocyte Colony-Stimulating Factor
3
Gemcitabine
3
Disulfides
3
Carmustine
3
venetoclax
2
tazemetostat
2
sodium-iodide symporter
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell
×
Solutions
×
1 year
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled